Document is current
Any future updates will be listed below
-
Authors
Mouri, Kousuke https://orcid.org/0000-0003-1712-6833
Guo, Michael H.
de Boer, Carl G. https://orcid.org/0000-0001-8935-5921
Lissner, Michelle M.
Harten, Ingrid A.
Newby, Gregory A.
DeBerg, Hannah A.
Platt, Winona F.
Gentili, Matteo https://orcid.org/0000-0002-6970-8133
Liu, David R. https://orcid.org/0000-0002-9943-7557
Campbell, Daniel J.
Hacohen, Nir https://orcid.org/0000-0002-2349-2656
Tewhey, Ryan https://orcid.org/0000-0002-4607-8001
Ray, John P. https://orcid.org/0000-0001-7294-4260
- License Information
-
More Information
Article History
Received: 11 May 2021
Accepted: 18 March 2022
First Online: 5 May 2022
Competing interests
: G.A.N. and D.R.L. have filed patent applications on genome-editing agents. D.R.L. is a consultant and equity owner of Beam Therapeutics, Prime Medicine and Pairwise Plants, companies that use genome editing. N.H. holds equity in BioNTech and consults for Related Sciences. The other authors declare no competing interests.
